141 related articles for article (PubMed ID: 38518059)
41. SF-36v2 and FACIT-Fatigue quality of life improvements with organ-specific SELENA-SLEDAI response and belimumab treatment in patients with systemic lupus erythematosus.
Rendas-Baum R; Chen WH; Gairy K; Anderson S; Henning C; Hammer A; Kosinski M
Lupus Sci Med; 2024 May; 11(1):. PubMed ID: 38724182
[TBL] [Abstract][Full Text] [Related]
42. Efficacy and safety of rituximab for systemic lupus erythematosus-associated immune cytopenias: A multicenter retrospective cohort study of 71 adults.
Serris A; Amoura Z; Canouï-Poitrine F; Terrier B; Hachulla E; Costedoat-Chalumeau N; Papo T; Lambotte O; Saadoun D; Hié M; Blanche P; Lioger B; Gottenberg JE; Godeau B; Michel M
Am J Hematol; 2018 Mar; 93(3):424-429. PubMed ID: 29247540
[TBL] [Abstract][Full Text] [Related]
43. Belimumab after B cell depletion therapy in patients with systemic lupus erythematosus (BEAT Lupus) protocol: a prospective multicentre, double-blind, randomised, placebo-controlled, 52-week phase II clinical trial.
Jones A; Muller P; Dore CJ; Ikeji F; Caverly E; Chowdhury K; Isenberg DA; Gordon C; Ehrenstein MR
BMJ Open; 2019 Dec; 9(12):e032569. PubMed ID: 31848169
[TBL] [Abstract][Full Text] [Related]
44. Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE.
Dooley MA; Houssiau F; Aranow C; D'Cruz DP; Askanase A; Roth DA; Zhong ZJ; Cooper S; Freimuth WW; Ginzler EM;
Lupus; 2013 Jan; 22(1):63-72. PubMed ID: 23263865
[TBL] [Abstract][Full Text] [Related]
45. Belimumab for the treatment of recalcitrant cutaneous lupus.
Vashisht P; Borghoff K; O'Dell JR; Hearth-Holmes M
Lupus; 2017 Jul; 26(8):857-864. PubMed ID: 28121495
[TBL] [Abstract][Full Text] [Related]
46. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response.
van Vollenhoven RF; Petri MA; Cervera R; Roth DA; Ji BN; Kleoudis CS; Zhong ZJ; Freimuth W
Ann Rheum Dis; 2012 Aug; 71(8):1343-9. PubMed ID: 22337213
[TBL] [Abstract][Full Text] [Related]
47. Safety and Efficacy of Belimumab Plus Standard Therapy for Up to Thirteen Years in Patients With Systemic Lupus Erythematosus.
Wallace DJ; Ginzler EM; Merrill JT; Furie RA; Stohl W; Chatham WW; Weinstein A; McKay JD; McCune WJ; Petri M; Fettiplace J; Roth DA; Ji B; Heath A
Arthritis Rheumatol; 2019 Jul; 71(7):1125-1134. PubMed ID: 30771238
[TBL] [Abstract][Full Text] [Related]
48. Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide study.
Iaccarino L; Andreoli L; Bocci EB; Bortoluzzi A; Ceccarelli F; Conti F; De Angelis R; De Marchi G; De Vita S; Di Matteo A; Emmi G; Emmi L; Gatto M; Gerli R; Gerosa M; Govoni M; Larosa M; Meroni PL; Mosca M; Pazzola G; Reggia R; Saccon F; Salvarani C; Tani C; Zen M; Frigo AC; Tincani A; Doria A
J Autoimmun; 2018 Jan; 86():1-8. PubMed ID: 28935492
[TBL] [Abstract][Full Text] [Related]
49. Evaluation of belimumab treatment in patients with systemic lupus erythematosus in a clinical practice setting: Results from a 24-month OBSErve study in Argentina.
Babini A; Cappuccio AM; Caprarulo C; Casado G; Eimon A; Figueredo H; García MA; Magri S; Mannucci P; Perez Rodriguez S; Pons-Estel BA; Velozo EJ; Iglesias-Rodriguez M; Streger G
Lupus; 2020 Oct; 29(11):1385-1396. PubMed ID: 32791930
[TBL] [Abstract][Full Text] [Related]
50. Effectiveness and safety of belimumab in patients with systemic lupus erythematosus in a real-world setting.
Anjo C; Mascaró JM; Espinosa G; Cervera R
Scand J Rheumatol; 2019 Nov; 48(6):469-473. PubMed ID: 31264525
[No Abstract] [Full Text] [Related]
51. [Lupus erythematosus treatment with belimumab in daily practice: Retrospective study of 15 patients].
Garval E; Pennaforte JL; Jaussaud R; Servettaz A; Bernard P; Reguiai Z
Ann Dermatol Venereol; 2018 Jan; 145(1):5-12. PubMed ID: 29113694
[TBL] [Abstract][Full Text] [Related]
52. Smoking and pre-existing organ damage reduce the efficacy of belimumab in systemic lupus erythematosus.
Parodis I; Sjöwall C; Jönsen A; Ramsköld D; Zickert A; Frodlund M; Sohrabian A; Arnaud L; Rönnelid J; Malmström V; Bengtsson AA; Gunnarsson I
Autoimmun Rev; 2017 Apr; 16(4):343-351. PubMed ID: 28216072
[TBL] [Abstract][Full Text] [Related]
53. Efficacy and safety of belimumab/low-dose cyclophosphamide therapy in moderate-to-severe systemic lupus erythematosus.
Cheng H; Zhang XY; Yang HD; Yu Z; Yan CL; Gao C; Wen HY
Front Immunol; 2022; 13():911730. PubMed ID: 35979351
[TBL] [Abstract][Full Text] [Related]
54. Long-Term Impact of Belimumab on Health-Related Quality of Life and Fatigue in Patients With Systemic Lupus Erythematosus: Six Years of Treatment.
Strand V; Berry P; Lin X; Asukai Y; Punwaney R; Ramachandran S
Arthritis Care Res (Hoboken); 2019 Jun; 71(6):829-838. PubMed ID: 30320964
[TBL] [Abstract][Full Text] [Related]
55. Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus.
Stohl W; Hiepe F; Latinis KM; Thomas M; Scheinberg MA; Clarke A; Aranow C; Wellborne FR; Abud-Mendoza C; Hough DR; Pineda L; Migone TS; Zhong ZJ; Freimuth WW; Chatham WW; ;
Arthritis Rheum; 2012 Jul; 64(7):2328-37. PubMed ID: 22275291
[TBL] [Abstract][Full Text] [Related]
56. A 6-month open-label extension study of the safety and efficacy of subcutaneous belimumab in patients with systemic lupus erythematosus.
Doria A; Bass D; Schwarting A; Hammer A; Gordon D; Scheinberg M; Fox NL; Groark J; Stohl W; Kleoudis C; Roth D
Lupus; 2018 Aug; 27(9):1489-1498. PubMed ID: 29807477
[TBL] [Abstract][Full Text] [Related]
57. Long-term safety and limited organ damage in patients with systemic lupus erythematosus treated with belimumab: a Phase III study extension.
van Vollenhoven RF; Navarra SV; Levy RA; Thomas M; Heath A; Lustine T; Adamkovic A; Fettiplace J; Wang ML; Ji B; Roth D
Rheumatology (Oxford); 2020 Feb; 59(2):281-291. PubMed ID: 31302695
[TBL] [Abstract][Full Text] [Related]
58. Initiation of belimumab with higher daily prednisolone is effective for rapid glucocorticoid reduction: A 96-week retrospective study.
Yamane T; Hashiramoto A
Lupus; 2024 May; 33(6):598-607. PubMed ID: 38509864
[TBL] [Abstract][Full Text] [Related]
59. Disease-modifying effect and long-term safety of belimumab in patients with systemic lupus erythematosus: A single-center retrospective study.
Nakai T; Fukui S; Sawada H; Ikada Y; Tamaki H; Kishimoto M; Okada M
Lupus; 2023 Nov; 32(13):1518-1527. PubMed ID: 37858981
[TBL] [Abstract][Full Text] [Related]
60. Favorable pregnancy outcomes in two patients with systemic lupus erythematosus treated with belimumab.
Wei SR; Zhu ZZ; Xu J; Mo HY
Int J Rheum Dis; 2023 Jan; 26(1):154-156. PubMed ID: 36165403
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]